A research report resulting from a collaboration between the University of Maryland and University of Michigan (USA) delivers a critical set of recommendations emphasizing the urgent need for policies that foster single global development of off patent medicines.
On 20 November, the CEO Advisory Committee of the International Generic and Biosimilar Medicines Association (IGBA) convened to discuss how the generics and biosimilars sector can continue to deliver on its mission—ensuring affordable, safe, effective and quality-assured therapies for patients— in a shifting international landscape.
At the WHO Global Forum for Public Procurement of Health Products, a powerful reminder was shared by WHO’s Director-General, Dr. Tedros Adhanom Ghebreyesus.
- Global Biosimilars Week 2025 Launches: Advancing Health Equity Through Wise Investment in Access to Medicines (November 2025)
- IGBA at UNGA Side Events (September 2025)
- IGBA Welcomes the WHO Pandemic Agreement and Calls for Action on Key Elements (July 2025)
- IGBA Statement at the 66th Series of Meetings of the WIPO Assemblies (July 2025)
